Determination of propranolol chloride content in generic, similar and manipulated medicinal product by ultraviolet-visible spectrophotometry
International Journal of Development Research
Determination of propranolol chloride content in generic, similar and manipulated medicinal product by ultraviolet-visible spectrophotometry
Received 28th August, 2019; Received in revised form 11th September, 2019; Accepted 19th October, 2019; Published online 30th November, 2019
Copyright © 2019, Camila Gonçalves Ramos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Propranolol Hydrochloride inhibits the stimulation of beta-adrenergic receptors (beta-1 and beta-2) present in the body such as the heart and blood vessels. It was the first successful beta-blocker developed, it is one of the most used drugs mainly in the treatment of hypertension, it is also indicated for the treatment and prevention of myocardial infarction, angina, cardiac arrhythmias, as well as migraine. However, this article aims to verify the Propranolol Hydrochloride content in Generic, Similar and Manipulated drug, by ultraviolet-visible spectrophotometry. It is an experimental research. Thus, the present research used Propranolol Hydrochloride in the Generic (G), Similar (S) and Manipulated (M) formulations. Propranolol hydrochloride content was determined using the UV-visible spectrophotometer method. Propranolol Hydrochloride tablets were purchased from a private pharmacy in Vitória da Conquista-Bahia. The results obtained in the analysis presented an average concentration of generic drug concentration 94.31%, similar 102.58% and manipulated 105.61%. According to the Brazilian Pharmacopoeia, the values must be between 90% and 110%. Thus, the drugs are suitable for consumption as the concentration content is within the required parameters.
